Health
in Motion

Sunday, October 27

11:00 A.M. – 11:45 A.M.

Why Perform Coronary Functional Testing (CFT)?

• Why perform CFT
• How to integrate CFT into your practice
• Procedure basics/workflow/protocol review
• Q&A

Important Safety Information
CoroFlow^‡ Cardiovascular System
PressureWire™ X Guidewire

3:15 P.M. – 4:00 P.M.

Advancing Coronary Microvascular Dysfunction (CMD) Studies: Case Studies, Interactive Conversation with Experts on Diagnosis and Treatment Options

• CFR/IMR/RRR- how these indices are derived and what they mean
• Interactive case reviews
• In depth Q&A: phenotype review

Monday, October 28

2:00 P.M. – 2:45 P.M.

Advancing Coronary Microvascular Dysfunction (CMD) Studies: Case Studies, Interactive Conversation with Experts on Diagnosis and Treatment Options

• CFR/IMR/RRR- how these indices are derived and what they mean
• Interactive case reviews
• In depth Q&A: phenotype review

Tuesday, October 29

11:00 A.M. – 11:45 A.M.

Why Perform Coronary Functional Testing (CFT)?

• Why perform CFT
• How to integrate CFT into your practice
• Procedure basics/workflow/protocol review
• Q&A

Monday, October 28

11:15 A.M. – 12:00 P.M.

OCT HANDS-ON TRAINING: ULTREON™ 2.0 SOFTWARE

A comprehensive training session on how to leverage clinical OCT insights powered by AI for better and quicker treatment decision-making.

How to use Ultreon™ 2.0 Software to:

• Quickly assess lesion morphology
• Choose the right lesion prep strategy based on OCT
• Leverage AI insights
• Confirm post-PCI results

Important Safety Information

Sunday, October 27
9:00 A.M., 10:00 A.M., 11:00 A.M., 1:00 P.M., 2:00 P.M., 3:00 P.M.
Runs every 30 minutes, top of hour

Monday, October 28
9:00 A.M., 10:00 A.M., 11:00 A.M., 1:00 P.M., 2:00 P.M., 3:00 P.M.
Runs every 30 minutes, top of hour

Tuesday, October 29
9:00 A.M., 10:00 A.M., 11:00 A.M., 1:00 P.M., 2:00 P.M., 3:00 P.M.
Runs every 30 minutes, top of hour

Wednesday, October 30
9:00 A.M., 10:00 A.M., 11:00 A.M.
Runs every 30 minutes, top of hour

MEET AN ESPRIT™ BTK EXPERT:

An opportunity to meet the team behind the development of Esprit™ BTK.

Monday, October 28

10:00 A.M. – 12:00 P.M.

Why Esprit™ BTK Design Matters?

Important Safety Information

MEET AN ESPRIT™ BTK EXPERT:

An opportunity for a hands-on interaction with Esprit™ BTK system and discussion with current users.

Monday, October 28

2:00 P.M. – 4:00 P.M.

How and Why I use Esprit™ BTK

MIXED-REALITY INTERACTION WITH ESPRIT™ BTK

An opportunity for a unique perspective and interaction.

SUNDAY, OCTOBER 27
12:00 P.M. – 2:00 P.M.

MONDAY, OCTOBER 28
12:00 P.M. – 2:00 P.M.

TUESDAY, OCTOBER 29
12:00 P.M. – 2:00 P.M.

WEDNESDAY, OCTOBER 30
12:00 P.M. – 2:00 P.M.

Sunday, October 27 | 8:15 A.M. – 8:23 A.M. | Presentation Theater 3

OCT-Guided vs. Angiography-Guided Coronary Stent Implantation in Calcified Lesions: An ILUMIEN IV Substudy

Sunday, October 27 | 9:10 A.M. – 9:20 A.M. | Moderated Abstracts Station 6

Pharmokinetic Profile of Everolimus Eluted from the Esprit™ BTK Scaffold: Data from the LIFE-BTK Pharmokinetics Sub-Study

Monday, October 28 | 2:00 P.M. – 2:08 P.M. | Endovascular Spotlight Room

Cost Effectiveness of Drug-Eluting Resorbable Scaffold vs. Angioplasty for Infrapopliteal Artery Disease from the LIFE-BTK Trial

Tuesday, October 29 | 11:00 A.M. | Main Arena

ECLIPSE: A Large-scale, Randomized Trial of Orbital Atherectomy vs. Conventional Balloon Angioplasty in Severely Calcified Coronary Arteries Prior to DES Implantation

Tuesday, October 29 | 11:10 A.M. - 11:20 A.M. | Moderated Abstracts Station 5

Impact of Intravascular Imaging on Clinical Outcomes in the LIFE-BTK Randomized Clinical Trial

Sunday, October 27 | 9:39 A.M. | Moderated Abstracts Station 4, Innovation & Exhibit Hall (Halls A-C)

Impact of Anterior, Posterior and Bi-leaflet Disease on Clinical Outcomes: Results from the EXPANDed Studies

Sunday, October 27 | 1:30 P.M. | Presentation Theater 3

TRILUMINATE Pivitol Trial: Outcomes in the Primary Analysis Population vs. Subsequent Enrollment

Sunday, October 27 | 1:45 P.M. | Presentation Theater 3

TriClip™ Outcomes in Patients With CIED Leads: Results From the TRILUMINATE Pivotal Trial

Important Safety Information

Sunday, October 27 | 2:00 P.M. | Presentation Theater 3

Multicentric Randomized Evaluation of Transcatheter Edge-to-Edge Repair for Severe Isolated Tricuspid Regurgitation: The TRI-FR Trial: Evolution Over Time of Transthoracic Echocardiography Parameters

Sunday, October 27 | 3:15 P.M. | Presentation Theater 3

M-TEER for Moderate to Severe FMR in Symptomatic Heart Failure: Comparison of RESHAPE-HF2 Trial Results with Outcomes in MITRA-FR and COAPT

Sunday, October 27 | 3:30 P.M. | Presentation Theater 3

Impact of MitraClip™ on Hospitalization Rates in Symptomatic Patients with Heart Failure and Moderate to Severe Functional Mitral Regurgitation: Insights from RESHAPE-HF2

Important Safety Information

Monday, October 28 | 11:49 A.M. | Innovation Theater, Innovation & Exhibit Hall (Hall A-C)

Two-Year Outcomes in the Navitor™ IDE Study Utilizing an Intra-Annular, Self-Expandable Transcatheter Aortic Heart Valve

Important Safety Information

Monday, October 28 | 11:56 A.M. | Innovation Theater, Innovation & Exhibit Hall (Hall A-C)

Comparative Data of Valve Performance Between Latest Generation Intra-Annular Versus Supra-Annular Self-Expandable Transcatheter Heart Valves in Small Aortic Annuli

Tuesday, October 29 | 12:00 P.M. | Innovation Theater, Innovation & Exhibit Hall (Hall A-C)

Primary Endpoint Results with the Second-Generation Cephea* Transseptal TMVR System in Complex Mitral Valve Disease

* Currently in development at Abbott. Not available for sale. Subject to change.

Tuesday, October 29 | 4:00 P.M. | Moderated Abstract Station 1

Patent Foramen Ovale Closure in Patients >60 Years: Age Stratified Results from U.S. Medicare Beneficiaries

Wednesday, October 30 | 10:14 A.M. | Innovation Theater

One-Year Real-World Outcomes with the Amulet LAAO: The EMERGE LAA Post-Approval Study

Important Safety Information

Wednesday, October 30 | 10:53 A.M. | Moderated Abstracts Station 2, Innovation & Exhibit Hall (Halls A-C)

Early US Commercial Experience with an Intra-Annular, Self-Expandable Valve in High-Risk Patients: 30-Day Results from the Navitor™ Post-Approval Study

Important Safety Information

Wednesday, October 30 | 3:12 P.M. | Main Arena

Transcatheter Repair versus Surgery in Atrial Mitral Regurgitation: Results from the MATTERHORN Trial